Literature DB >> 27236000

Simultaneous measurement of etravirine, maraviroc and raltegravir in pigtail macaque plasma, vaginal secretions and vaginal tissue using a LC-MS/MS assay.

Anna K Blakney1, Yonghou Jiang1, Dale Whittington2, Kim A Woodrow3.   

Abstract

Etravirine (ETR), maraviroc (MVC) and raltegravir (RAL) are promising antiretroviral drugs being used in HIV treatment and may be interesting for prevention applications such as oral or topical pre-exposure prophylaxis. Here we describe a sensitive and accurate method for the simultaneous detection of ETR, MVC and RAL from pigtail macaque plasma, vaginal secretions, and vaginal tissue. This method is characterized by a straightforward precipitation extraction method, a limit of quantification <0.5ngmL(-1) for all three antiretrovirals bolstered by a corresponding internal standard for each drug analyte, and short run time. Quantification is performed using positive ion electrospray triple quadrupole mass spectrometry. This method was validated over clinically relevant ranges for the three ARV drugs in all three matrices: 0.1-100ngmL(-1) for ETR, 0.05-100ngmL(-1) for MVC and 1-100ngmL(-1) for RAL. Our method is accurate and precise, with measured mean inter-assay precision (%CV) and accuracy (% bias) of 5.08% and 1.96%, respectively, while the mean intra-assay precision and accuracy were 3.44% and 1.08%. The overall post-extraction recovery for ETR, MVC and RAL was >94% in all cases. We also show that extracted biological samples are stable after storage at room temperature or 4°C and after three freeze/thaw cycles. This is the first analytical method capable of quantifying ETR, MVC and RAL in biological matrices relevant for pre-clinical testing of oral or topical HIV prevention methods in pigtailed macaques. Published by Elsevier B.V.

Entities:  

Keywords:  Etravirine; Maraviroc; Plasma; Raltegravir; Vaginal secretions; Vaginal tissue

Mesh:

Substances:

Year:  2016        PMID: 27236000      PMCID: PMC4922635          DOI: 10.1016/j.jchromb.2016.04.048

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  38 in total

1.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

2.  An LC-MS-MS method for quantitative determination of maraviroc (UK-427,857) in human plasma, urine and cerebrospinal fluid.

Authors:  Ed Brewer; Tonya Felix; Phil Clarke; Alan Edgington; David Muirhead
Journal:  Biomed Chromatogr       Date:  2010-12       Impact factor: 1.902

3.  Pharmacokinetics of a CCR5 inhibitor in rhesus macaques following vaginal, rectal and oral application.

Authors:  R Karl Malcolm; Deborah Lowry; Peter Boyd; Leslie Geer; Ronald S Veazey; Laurie Goldman; P J Klasse; Robin J Shattock; John P Moore
Journal:  J Antimicrob Chemother       Date:  2013-12-30       Impact factor: 5.790

Review 4.  Electrospun fibers for vaginal anti-HIV drug delivery.

Authors:  Anna K Blakney; Cameron Ball; Emily A Krogstad; Kim A Woodrow
Journal:  Antiviral Res       Date:  2013-11-01       Impact factor: 5.970

5.  Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir.

Authors:  Diarmaid J Murphy; Delphine Desjardins; Nathalie Dereuddre-Bosquet; Patricia Brochard; Ludivine Perrot; Alain Pruvost; Roger Le Grand; Ole Lagatie; Leen Vanhooren; Maxim Feyaerts; Jens van Roey; R Karl Malcolm
Journal:  J Antimicrob Chemother       Date:  2014-05-26       Impact factor: 5.790

6.  Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women.

Authors:  Salim S Abdool Karim; Angela D M Kashuba; Lise Werner; Quarraisha Abdool Karim
Journal:  Lancet       Date:  2011-07-16       Impact factor: 79.321

Review 7.  Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence.

Authors:  Connie Celum; Jared M Baeten
Journal:  Curr Opin Infect Dis       Date:  2012-02       Impact factor: 4.915

Review 8.  The evolution of HIV treatment guidelines: current state-of-the-art of ART.

Authors:  Andrew R Zolopa
Journal:  Antiviral Res       Date:  2009-10-31       Impact factor: 5.970

9.  Postexposure protection of macaques from vaginal SHIV infection by topical integrase inhibitors.

Authors:  Charles Dobard; Sunita Sharma; Urvi M Parikh; Rolieria West; Andrew Taylor; Amy Martin; Chou-Pong Pau; Debra L Hanson; Jonathan Lipscomb; James Smith; Francis Novembre; Daria Hazuda; J Gerardo Garcia-Lerma; Walid Heneine
Journal:  Sci Transl Med       Date:  2014-03-12       Impact factor: 17.956

10.  A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine.

Authors:  A Fayet; A Béguin; B Zanolari; S Cruchon; N Guignard; A Telenti; M Cavassini; H F Günthard; T Buclin; J Biollaz; B Rochat; L A Decosterd
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-02-28       Impact factor: 3.205

View more
  1 in total

1.  Glycan targeted polymeric antibiotic prodrugs for alveolar macrophage infections.

Authors:  Jasmin Chen; Fang-Yi Su; Debobrato Das; Selvi Srinivasan; Hye-Nam Son; Brian Lee; Frank Radella; Dale Whittington; Taylor Monroe-Jones; T Eoin West; Anthony J Convertine; Shawn J Skerrett; Patrick S Stayton; Daniel M Ratner
Journal:  Biomaterials       Date:  2018-10-16       Impact factor: 12.479

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.